82 related articles for article (PubMed ID: 27031828)
1. Weight Loss Associated with Platinum-Based Chemotherapy in Patients with Advanced Lung Cancer.
Morio K; Minami T; Sozu T; Niki K; Kijima T; Uejima E; Morio K
Chemotherapy; 2016; 61(5):256-61. PubMed ID: 27031828
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Garassino MC; Torri V; Michetti G; Lo Dico M; La Verde N; Aglione S; Mancuso A; Gallerani E; Galetta D; Martelli O; Collovà E; Fatigoni S; Ghidini A; Saggia C; Bareggi C; Rossi A; Farina G; Thatcher N; Blackhall F; Lorigan P; Califano R
Lung Cancer; 2011 Jun; 72(3):378-83. PubMed ID: 20950888
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
Lee GW; Go SI; Cho YJ; Jeong YY; Kim HC; Duk Lee J; Hwang YS; Ko GH; Lee JH; Kim DC; Yang JW; Oh S; Lee JS
J Thorac Oncol; 2012 Mar; 7(3):528-34. PubMed ID: 22258474
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?
Sun JM; Ahn MJ; Ahn JS; Um SW; Kim H; Kim HK; Choi YS; Han J; Kim J; Kwon OJ; Shim YM; Park K
Lung Cancer; 2012 Aug; 77(2):365-70. PubMed ID: 22579297
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with non-small-cell lung cancer after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine.
Imai H; Shukuya T; Yoshino R; Muraki K; Mori K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Tomizawa Y; Takahashi T; Takahashi K; Saito R; Yamamoto N
Chemotherapy; 2013; 59(4):307-13. PubMed ID: 24480845
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
[TBL] [Abstract][Full Text] [Related]
10. Third-line chemotherapy in small-cell lung cancer: an international analysis.
Simos D; Sajjady G; Sergi M; Liew MS; Califano R; Ho C; Leighl N; White S; Summers Y; Petrcich W; Wheatley-Price P
Clin Lung Cancer; 2014 Mar; 15(2):110-8. PubMed ID: 24365050
[TBL] [Abstract][Full Text] [Related]
11. Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: a retrospective study of 300 patients.
Nagy-Mignotte H; Guillem P; Vignoud L; Coudurier M; Vesin A; Bonneterre V; Toffart AC; Sakhri L; Brambilla C; Brambilla E; Timsit JF; Moro-Sibilot D;
Lung Cancer; 2012 Oct; 78(1):112-20. PubMed ID: 22795703
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
[TBL] [Abstract][Full Text] [Related]
14. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.
Kim SJ; Kim JS; Kim SC; Kim YK; Kim YK; Kang JY; Yoon HK; Song JS; Lee SH; Moon HS; Kim JW; Kim KH; Kim CH; Shim BY; Kim HK
Lung Cancer; 2010 Jun; 68(3):446-9. PubMed ID: 19683359
[TBL] [Abstract][Full Text] [Related]
16. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of chemotherapy, especially combined therapy with Carboplatin Plus Etoposide(CE), in patients aged > or =80 years old with extensive-disease small-cell lung cancer].
Tamiya A; Tsuya A; Nakamura Y; Kaira K; Naitou T; Murakami H; Takahashi T; Endo M; Yamamoto N
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1041-4. PubMed ID: 20567104
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
Iranzo V; Sirera R; Bremnes RM; Blasco A; Jantus-Lewintre E; Tarón M; Berrocal A; Blasco S; Caballero C; Del Pozo N; Rosell R; Camps C
Clin Lung Cancer; 2011 Jul; 12(4):224-30. PubMed ID: 21726821
[TBL] [Abstract][Full Text] [Related]
19. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of the Efficacy and Safety of Platinum Doublet Re-Challenge Chemotherapy in Patients with Recurrent Advanced Non-Small Cell Lung Cancer].
Mori A; Hirose T; Tamura A; Kusaka K; Matsui H; Ohta K
Gan To Kagaku Ryoho; 2016 Jun; 43(6):723-6. PubMed ID: 27306808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
